目的 探讨奥扎格雷氨丁三醇注射用浓溶液联合丹红注射液治疗急性脑梗死的临床效果。方法 收集无锡市锡山人民医院2024年1月—2025年12月收治的98例急性脑梗死患者的临床资料，根据治疗方案分为对照组（50例）和治疗组（48例）。对照组静脉滴注丹红注射液，40 mL丹红注射液＋250 mL 0.9%氯化钠溶液，1次/d。治疗组患者在对照组基础上静脉滴注奥扎格雷氨丁三醇注射用浓溶液，5 mL奥扎格雷氨丁三醇注射用浓溶液＋250 mL 0.9%氯化钠溶液，2次/d。两组均连续治疗14 d。比较两组的临床疗效、血清学指标、凝血功能和预后情况。结果 治疗后，治疗组的总有效率为89.58%，显著高于对照组的总有效率70.00%（P＜0.05）。治疗后，两组血清脂蛋白相关磷脂酶A2（Lp-PLA2）、同型半胱氨酸（Hcy）、神经元特异性烯醇化酶（NSE）水平均显著降低（P＜0.05），且治疗组血清Lp-PLA2、Hcy、NSE水平均低于对照组（P＜0.05）。治疗后，两组凝血酶原时间（PT）、凝血酶时间（TT）、活化部分凝血活酶时间（APTT）水平均显著升高，纤维蛋白原（FIB）水平显著降低（P＜0.05），且治疗组的PT、TT、APTT水平显著高于对照组，FIB水平显著低于对照组（P＜0.05）。治疗后随访90 d，治疗组预后优良率为95.83%，显著高于对照组优良率82.00%（P＜0.05）。结论 奥扎格雷氨丁三醇注射用浓溶液联合丹红注射液治疗急性脑梗死的疗效显著，可有效降低神经损伤标志物水平，改善凝血功能，提升预后质量。

Objective To investigate the clinical efficacy of Ozagrel Trometamol Concentrated Solution for injection combined with Danhong Injection in treatment of acute cerebral infarction. Methods Clinical data were collected from 98 patients with acute cerebral infarction admitted to Wuxi Xishan People’s Hospital from January 2024 to December 2025. All patients were divided into control group (50 cases) and treatment group (48 cases) based on the treatment regimen. The control group received intravenous drip infusion of Danshu Injection (40 mL Danshu Injection + 250 mL 0.9% sodium chloride solution), once daily. The treatment group received intravenous drip infusion of Ozagrel Trometamol Concentrated Solution for injection (5 mL Ozagrel Trometamol Concentrated Solution for injection + 250 mL 0.9% sodium chloride solution) on the basis of the control group, twice daily. Two groups were treated continuously for 14 days. The clinical efficacy, serum indicators, coagulation function, and prognosis were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 89.58%, significantly higher than the total effective rate of 70.00% in the control group (P < 0.05). After treatment, the serum levels of lipoprotein related phospholipase A2 (Lp-PLA2), homocysteine (Hcy), and neuron specific enolase (NSE) in two groups were significantly reduced (P < 0.05), and the serum levels of Lp-PLA2, Hcy, and NSE in the treatment group were lower than those in the control group (P < 0.05). After treatment, the levels of prothrombin time (PT), thrombin time (TT), and activated partial thromboplastin time (APTT) significantly increased in two groups, while fibrinogen (FIB) levels significantly decreased (P < 0.05). The PT, TT, and APTT levels in the treatment group were significantly higher than those in the control group, while FIB levels were significantly lower than those in the control group (P < 0.05). After 90 days of follow-up after treatment, the excellent and good prognosis rate of the treatment group was 95.83%, significantly higher than the control group's excellent and good prognosis rate of 82.00% (P < 0.05). Conclusion The clinical effect of Ozagrel Trometamol Concentrated Solution for injection combined with Danhong Injection is significant in treatment of acute cerebral infarction, which can effectively reduce the level of nerve injury markers, improve coagulation function, and enhance prognosis quality.

R971